- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Marvel Biosciences Corp.: New Autism Research to be Presented at European Purine Scientific Meeting | 1 | GlobeNewswire (USA) | ||
| 08.06. | Marvel Biosciences Corp: Marvel gains Australian patent allowance for MB-204 | 1 | Stockwatch | ||
| 08.06. | Marvel Biosciences Corp.: Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204 | 160 | GlobeNewswire (Europe) | CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel")... ► Artikel lesen | |
| 20.05. | Marvel Biosciences Corp: Marvel Biosciences grants 50,001 DSUs to 3 directors | 1 | Stockwatch | ||
| 20.05. | Marvel Biosciences Corp.: Marvel Biosciences Announces Grant of Deferred Share Units | 224 | Newsfile | Calgary, Alberta--(Newsfile Corp. - May 20, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces... ► Artikel lesen | |
| 30.04. | Marvel Biosciences Corp: Marvel Biosciences $500,000 debenture private placement | 3 | Stockwatch | ||
| MARVEL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 23.04. | Marvel Biosciences Corp.: Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit | 1 | GlobeNewswire (USA) | ||
| 17.04. | Marvel Biosciences Corp: Marvel Biosciences closes $500,000 debenture offering | 2 | Stockwatch | ||
| 17.04. | Marvel Biosciences Corp.: Marvel Biosciences Announces Closing of Convertible Debenture Offering | 736 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today that it has completed the closing of the previously announced... ► Artikel lesen | |
| 16.04. | Marvel Biosciences Corp: Marvel Biosciences develops MB-204 liquid formulations | 3 | Stockwatch | ||
| 16.04. | Marvel Biosciences advancing autism drug for children | 1 | The Market Online Canada | ||
| 16.04. | Marvel Biosciences Corp.: Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders | 177 | GlobeNewswire (Europe) | CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company")... ► Artikel lesen | |
| 14.04. | Marvel Biosciences Corp: Marvel Biosciences amends debenture conversion price | 1 | Stockwatch | ||
| 13.04. | Marvel Biosciences lowers conversion price for proposed debenture offering | 1 | Seeking Alpha | ||
| 13.04. | Marvel Biosciences Corp.: Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering | 443 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") Further to the Company's press release of April 8, 2026, announcing its intention... ► Artikel lesen | |
| 08.04. | Marvel Biosciences plans convertible debenture private placement | 3 | Seeking Alpha | ||
| 08.04. | Marvel Biosciences Corp.: Marvel Biosciences Announces Proposed Convertible Debenture Offering | 470 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement... ► Artikel lesen | |
| 07.04. | Marvel Biosciences Corp: Marvel Biosciences gets backing from 5 Horizons | 5 | Stockwatch | ||
| 07.04. | Marvel Biosciences Corp.: Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures | 418 | GlobeNewswire (Europe) | CALGARY, Alberta, April 07, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL - OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company")... ► Artikel lesen | |
| 30.03. | Marvel Biosciences Corp: Marvel obtains Alberta funding for MB-204 phase I | 1 | Stockwatch |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,66 | +0,04 % | Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy | ||
| PRAXIS PRECISION MEDICINES | 349,93 | -0,18 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 32,550 | -0,03 % | Jefferies upgrades Tango Therapeutics stock rating on cancer trial data | ||
| VERA THERAPEUTICS | 43,130 | -0,05 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 109,43 | +0,10 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| ERASCA | 18,290 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,740 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,340 | 0,00 % | Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline | ||
| MINERALYS THERAPEUTICS | 26,880 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 62,41 | 0,00 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| ABSCI | 11,345 | -0,04 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,310 | -0,07 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RELAY THERAPEUTICS | 19,740 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,950 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 50,86 | +0,02 % | Jones Trading raises Enliven Therapeutics price target on CML trials |
Das Unternehmen MARVEL BIOSCIENCES CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MARVEL BIOSCIENCES CORP finden Sie auf Wallstreet Online.